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Exploratory activityAbstract Background: Fluoxetine, a selective serotonin re-uptake inhibitor (SSRI), has been
proposed to be more effective as an antidepressive drug as compared to other SSRIs. After chronic
SSRI administration, the increase in synaptic levels of 5-HT leads to desensitization of somatoden-
tritic 5-HT autoreceptors in the raphe nuclei. Chronic stress may alter behavioral, neurochemical
and physiological responses to drug challenges and novel stressors.Methods: Twenty four male rats
were used in this study. Animals of CMS group were exposed to CMS. Animals of stressed and
unstressed group were administrated with ﬂuoxetine at dose of 1.0 mg/kg s well as 5.0 mg/kg repeat-
edly for 07 days 1 h before exposed to CMS. The objective of the present study was to evaluate that
repeated treatment with ﬂuoxetine could attenuate CMS-induced behavioral deﬁcits. Results:
Treatment with ﬂuoxetine attenuated CMS-induced behavioral deﬁcits. Fluoxetine administration
induced hypophagia in unstressed as well as CMS rats. Acute and repeated administration of ﬂuox-
etine increased motor activity in familiar environment but only repeated administration increased
exploratory activity in open ﬁeld. Anxiolytic effects of ﬂuoxetine were greater in unstressed rats.
These anxiolytic effects were produced as result of repeated administration not on acute administra-
tion of ﬂuoxetine at 1.0 mg/kg as well as 5.0 mg/kg. Conclusion: The present study demonstrated
that CMS exposure resulted into behavioral deﬁcits and produced depressive-like symptoms.
572 M. Farhan, D.J. HaleemFluoxetine, an SSRI, administration attenuated behavioral deﬁcits induced by CMS. Anxiolytic
effects of repeated ﬂuoxetine administration were greater in unstressed than CMS animals.
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an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Table 1 Chronic mild stress (CMS) schedule.
S.# Day CMS Time
1 Day 1 Exposed to 4 C for 50 min 11:00 am
2 Day 2 60 min cage agitation (60 rpm) 11:00 am
3 Day 3 60 min restrained stress
(wire grid)
11:00 am
4 Day 4 12 h water deprivation 11:00 am–
11:00 pm
5 Day 5 3 h light oﬀ day time 11:00 am–
02:00 pm
6 Day 6 60 min noise stress 11:00 am
7 Day 7 60 min restraint stress (tube) 11:00 am1. Introduction
The term stress was originally deﬁned by Hans Selye, in the
1940’s (Selye and Fortier, 1949), as the nonspeciﬁc reaction
of an organism to adverse stimuli. Stress is characterized as
an adaptive response (physical, mental or emotional) toward
events capable of causing shifts on the homeostasis in the
organism, allowing it to maximize its chances of survival when
facing a challenge. Berger (1980) deﬁned stress as the total sum
of the bodily responses which occurs in response of adaptation
of changes by the organisms (Berger, 1980). There is increasing
evidence that stress affects health not only through its direct
biological effects but also through changes in health behavior
that they inﬂuence health (Siperoe, 1991; Alder and Mathews,
1994). Stress exposure caused activation of sympathetic ner-
vous system (Dunn and Welch, 1991). Stress can lead to a
number of diseases such as as hypertension, anxiety, headache,
gastritis, ulcerative colitis, migraine, asthma and depression
(Gardner, 1975; Tortora and Anagnostakos, 1990).
It has been reported that chronic mild stress models are
comparatively more suitable than acute stress models for
investigating depression in experimental models (Katz et al.,
1981; Willner et al., 1987). A previous study has reported that
exposure to unpredictable stressors induces signiﬁcant changes
in behavioral parameters (Farhan et al., 2014) such as altered
locomotive and explorative behavior, a decline in food intake,
water intake and sexual activity (Willner et al., 1991). It has
also been suggested that chronic mild stress-induced behav-
ioral deﬁcits in experimental animals could be used effectively
as an animal model of depression (D’Aquila et al., 2000). In
addition to anhedonia, CMS has shown to decrease aggressive
and male sexual behavior in rats (D’Aquila and Brain, 1994).
Selective serotonin reuptake inhibitors (SSRIs) are themajor
and dominant class of antidepressants used over the last decade
whereas ancient groups of most widely used antidepressants
were Tricyclic antidepressants (TCA) and monoamine oxidase
inhibitors, ancient groups of antidepressants. (Artigas et al.,
2001). Fluoxetine, a selective serotonin re-uptake inhibitor
(SSRI), has been proposed as more effective as an antiaggres-
sive drug when compared with other SSRIs (Detke et al.,
1995; Contreras et al., 2001). A number of studies have reported
that ﬂuoxetine as well effective in treating a wide spectrum of
mood disorders including depression, panic disorder and anxi-
ety (Kindler et al., 1997; Mancini and Ameringen, 1996).
After chronic SSRI administration, the increase in synaptic
levels of 5-HT leads to desensitization of somatodentritic 5-HT
autoreceptors in the raphe nuclei. Both SSRIs and anxiolytic
5-HT receptor agonists can desensitize the somatodentritic 5-
HT-1A autoreceptors in the raphe nuclei, and subsequently
induce a sustained elevation of 5-HT in the synaptic cleft.
However, this desensitization occurs within 3 days of drug
administration, a time-course that is shorter than the delayed
onset of therapeutic improvement and may correlate with an
initial aggravation of anxiety (Boyer and Feighner, 1992;
Kahn et al., 1988a,b). Most of the effects induced by CMScan also be reversed by selective serotonin reuptake inhibitors
(SSRIs) Willner et al., 1987; Willner, 1997; Isingrini et al.,
2010, illustrating a strong predictive validity. Fluoxetine, a
SSRI also exhibits antidepressant activity in experimental
models (Detke et al., 1995; Contreras et al., 2001) and clinical
trials (Stoke and Holtz, 1997; Vaswani et al., 2003). It has been
reported that ﬂuoxetine increases serotonergic transmission in
synaptic cleft (Stahl, 1996). The present study was designed to
evaluate the ability of ﬂuoxetine to reverse CMS-induced
depression-like behavior in rats.
2. Materials and methods
2.1. Animals
Locally bred male (180–220 g) albino-Wistar rats purchased
from Aga Khan University, Karachi, Pakistan were housed
individually under 12-h light and dark cycle and controlled
room temperature (25 ± 2 C) with free access to cubes of
standard rodent diet and water, for a period of three days
before experimentation.
2.2. Drugs and doses
Fluoxetine, purchased from Merck Company was dissolved in
distilled water and administrated orally at a dose of 1 mg/kg as
well as 5 mg/kg and control animals were administrated with
water by using stainless steel feeding tubes.
2.3. Experimental protocol
Thirty-six animals were randomly divided into two equal
groups (i) Unstressed and (ii) CMS. Animals of both groups
were further divided into three groups (i) Unstressed-Water
(ii) Unstressed-Fluoxetine (1.0 mg/kg), (iii) Unstressed-
Fluoxetine (5.0 mg/kg), (iv) CMS-Water (v) CMS-Fluoxetine
(1.0 mg/kg) and (vi) CMS-Fluoxetine (5.0 mg/kg). Animals
of the CMS group were exposed to a schedule of chronic mild
stress shown below over a period of 14 days (Table 1) while
animals of unstressed groups remained in their home cages.
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Figure 1 Effects of administration of ﬂuoxetine (1.0 mg/kg and
5.0 mg/kg) of activity in familiar environment in unstressed and
CMS rats. Values are means + SD (n= 6) as monitored on next
day of the administration. Signiﬁcant differences by Newman–
Keuls test: *p< 0.05, **p< 0.01 from respective unstressed
animals; +p< 0.05, ++p< 0.01 from respective water treated
unstressed or CMS animals following three-way ANOVA
(repeated measure design).
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5.0 mg/kg) was given orally to animals each day 1 h before
exposing to daily schedule of CMS (Table 1). Locomotor
activity was monitored in familiar environment (activity box)
and in novel environment (open ﬁeld) on next day of 1st and
7th stress. Activities in light compartment of light dark activity
box and in open arm of elevated plus maze were monitored on
next day of 1st and 7th stress.
2.4. Behavioral assessment
2.4.1. Activity box
The assessment of locomotor activity in a familiar environ-
ment was done in activity box. Apparatus used in this study
was made up of transparent perspex (26 · 26 · 26 cm) with
saw dust covered ﬂoor. Testing was done in a quiet room
under white light as described by Haleem et al, (2007);
Ikram et al. (2011), 15 min before monitoring the activity ani-
mals were placed in the home cage for habituation. Numbers
of cage crossings were monitored for 10 min.
2.4.2. Open ﬁeld activity
The assessment of exploratory activity in a novel environment
was done in an open ﬁeld apparatus. Open ﬁeld apparatus used
in present investigation consisted of a square area (76 · 76 cm)
with walls 42 cm high. The ﬂoor was divided by lines into 25
equal squares. To determine the activity rats were placed in
the center squarer of the open ﬁeld. Numbers of square crossed
with all four paws were recorded for 5 min.
2.4.3. Light dark box activity
Activity in a light–dark box is used as animal model of anxiety
(Shimada et al., 1995). The test was conducted in a locally made
compartment box. The compartment of equal size
(26 · 26 · 26 cm), with an access (12 · 12 cm) between the com-
partments, differed in their sensory properties. The coverings
and walls of one compartment were light (transparent) and
other dark (black). To determine the activity a rat was intro-
duced in the middle of the light compartment of the box.
Entries and time spent in the light compartment were moni-
tored for a cut off time of 5 min. Entry into a compartment
of the box is deﬁned as the placement of all four paws in the
compartment of the activity box (Bourin and Hascoet, 2003).
2.4.4. Elevated plus maze test
The elevated plus maze is also widely used as animal model of
anxiety (Pellow et al., 1985). The plus maze apparatus used in
the present investigation was specially designed in our
laboratory and it consists of four arms in which two were open
and two were closed. The arms were of identical length (50 cm)
and width (10 cm). Arms were joined by central area of 5 cm2.
The maze was elevated from the ﬂoor as a height of 60 cm. To
determine the activity a rat was placed in the center of the plus
maze and time spent and the entries in the open arm were
determined for 5 min.
2.5. Statistical analysis
Values are means ± SD. Data were analyzed by three-way
ANOVA (repeated measures design). Software used for theanalysis was SPSS (version 17). Post-hoc comparison was done
by Newman–Keuls test. Values of p< 0.05 were considered as
signiﬁcant.
3. Results
Fig. 1 shows effects of repeated ﬂuoxetine administration on
activity in familiar environment (activity box) of rats exposed
to CMS as monitored on next day of 1st and 7th stress. Data
on number of cage crossing as analyzed by three-way ANOVA
(repeated measures design) showed that effects of stress
(F= 120.30; df = 1, 32; p< 0.01), ﬂuoxetine (F= 52.02;
df = 2, 32; p< 0.01), repeated monitoring (F= 42.45;
df = 3, 32; p< 0.01) and the interaction among all the factors
(F= 22.20; df = 6, 64; p< 0.01) were signiﬁcant. Post-hoc
analysis by Newman–Keuls test showed that exposure to
CMS decreased number of cage crossed in water administered
animals after 7th day of stress. Fluoxetine administration
574 M. Farhan, D.J. Haleemincreased activity in activity box of unstressed animals and val-
ues were signiﬁcantly higher after 7th day of administration of
1.0 mg/kg as well as 5.0 mg/kg ﬂuoxetine treated animals.
Exposure of ﬂuoxetine administered animals to CMS, resulted
to decrease in activity and difference were signiﬁcant after a
week of stress exposure in 1.0 mg/kg as well as 5.0 mg/kg
ﬂuoxetine administered animals.
Fig. 2 shows effects of repeated ﬂuoxetine administration
on activity in light dark transition box of rats exposed to
CMS as monitored on next day of 1stand 7th stress. Data
(Fig. 2a) on number of entries in light box as analyzed by
three-way ANOVA (repeated measures design) showed that
effects of stress (F= 152.25; df = 1, 32; p< 0.01), ﬂuoxetine
(F= 8.70; df = 2, 32; p< 0.01), repeated monitoring
(F= 21.51; df = 3, 32; p< 0.01) and the interaction
(F= 8.31; df = 6, 64; p< 0.01) were signiﬁcant. Post-hoc
analysis by Newman–Keuls test showed that exposure to
CMS decreased number of entries in light box in water treated
animals after 7th day of stress. Fluoxetine administration
increased activity of unstressed as well as CMS animals as(a) Number of entries in light box
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Figure 2 Effects of administration of ﬂuoxetine (1.0 mg/kg and 5.0 m
Values are means + SD (n= 6) as monitored on next day of the admin
from respective unstressed animals; +p< 0.01 from respective water
(repeated measure design).compared to similarly treated water administrated animals
but values were not signiﬁcant.
Data (Fig. 2b) on time spent in light box as analyzed by
three-way ANOVA (repeated measures design) showed that
effects of administration of ﬂuoxetine (F= 40.24; df = 2, 32;
p< 0.01), effects of repeated monitoring (F= 28.22; df = 3,
32; p< 0.01), effects of CMS (F= 113.78; df = 1, 32;
p< 0.01) and the interaction among all the factors
(F= 27.16; df = 6, 64; p< 0.01) were signiﬁcant. Post-hoc
analysis by Newman–Keuls test showed that CMS decreased
activity in water treated animals after 7th day of stress than
unstressed animals. Administration of ﬂuoxetine increased
activity in unstressed as well as CMS animals as compared to
water administrated unstressed or CMS animals respectively.
Values were signiﬁcant after 7th administration in 1.0 mg/kg
as well as 5.0 mg/kg ﬂuoxetine administrated animals.
Exposure to CMS decreased activity in ﬂuoxetine admini-
strated animals as compared to similarly administrated
unstressed animals and values were signiﬁcant after 1st and
7th day in 1.0 mg/kg ﬂuoxetine treated animals.(b) Time spent in light box
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istration. Signiﬁcant differences by Newman–Keuls test: *p< 0.01
treated unstressed or CMS animals following three-way ANOVA
(a) Number of entries in open arm (b) Time spent in open arm
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Figure 3 Effects of administration of ﬂuoxetine (1.0 mg/kg and 5.0 mg/kg) on activities in elevated plus maze of unstressed and CMS
rats. Values are means + SD (n= 6) as monitored on next day of the administration. Signiﬁcant differences by Newman–Keuls test:
*p< 0.05, **p< 0.01 from respective unstressed animals; +p< 0.01 from respective water treated unstressed or CMS animals; #p< 0.05,
##p< 0.01 from respective day 1.0 mg/kg ﬂuoxetine treated unstressed or CMS animals following three-way ANOVA (repeated measure
design).
Anxiolytic proﬁle of ﬂuoxetine in rat model of chronic mild stress 575Administration of ﬂuoxetine increased activity in unstressed
and CMS animals’ then water treated animals and values were
signiﬁcantly higher after one week treatment in unstressed and
CMS groups of 1.0 mg/kg as well as 5.0 mg/kg ﬂuoxetine
treated animals.
Fig. 3 shows effects of repeated ﬂuoxetine administration
on activity in light dark box of rats exposed to CMS as
monitored on next day of 1st and 7th stress. Data (Fig. 3a)
on number of entries in open arm as analyzed by three-way
ANOVA (repeated measures design) showed that effects of
repeated monitoring (F= 20.26; df = 3, 32; p< 0.01), effect
of CMS (F= 114.89; df = 1, 32; p< 0.01), effects of ﬂuoxe-
tine (F= 51.43; df = 2, 32; p< 0.01) were signiﬁcant.
Interaction among repeated monitoring, ﬂuoxetine administra-
tion and CMS (F= 7.47; df = 6, 64; p< 0.01) were also
signiﬁcant on counts of entries in open arm. Post-hoc analysis
by Newman–Keuls test showed that exposure to CMS
decreased activity (number of entries in open arm) in water
treated animals than unstressed animals after 7th day of stress.
Administration of ﬂuoxetine increased activity of
unstressed as well as CMS animals as compared to water
administrated unstressed or CMS animals respectively.Values were signiﬁcantly higher after 7th day of administration
in 5.0 mg/kg ﬂuoxetine administrated animals. CMS decreased
activity in ﬂuoxetine administrated animals as compared to
similarly administrated unstressed animals and values were
signiﬁcant after 7th day of CMS in 1.0 mg/kg as well as
5.0 mg/kg ﬂuoxetine administrated animals.
Data (Fig. 3b) on time spent in open arm as analyzed by
three- way ANOVA (repeated measures design) showed that
effects of ﬂuoxetine (F= 30.07; df = 2, 32; p< 0.01),
repeated monitoring (F= 21.09 df = 3, 32; p< 0.01), CMS
(F= 80.74; df = 1, 32; p< 0.01) and the interaction among
all the factors (F= 25.89; df = 6, 64; p< 0.01) were signiﬁ-
cant. Post-hoc analysis by Newman–Keuls test showed that
exposure to CMS decreased activity in water treated animals
after 7th day of stress as compared to similarly administrated
unstressed animals on the same respective days. Fluoxetine
administration increased activity in unstressed and CMS ani-
mals than water treated unstressed and CMS animals. Values
were signiﬁcantly higher after 7th of 5.0 mg/kg ﬂuoxetine
administrated animals but not signiﬁcant change was found
in 1.0 mg/kg ﬂuoxetine administrated animals. Exposure to
CMS decreased activity in ﬂuoxetine administrated animals
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Figure 4 Effects of administration of ﬂuoxetine (1.0 mg/kg and
5.0 mg/kg) on activity in open ﬁeld in unstressed and CMS rats.
Values are means + SD (n= 6) as monitored on next day of the
administration. Signiﬁcant differences by Newman–Keuls test:
*p< 0.05, **p< 0.01 from respective unstressed animals;
+p< 0.05, ++p< 0.01 from respective water treated unstressed
or CMS animals; following three-way ANOVA (repeated measure
design).
576 M. Farhan, D.J. Haleemas compared to similarly administrated unstressed animals and
values were signiﬁcantly smaller after 7th day of CMS schedule
in 1.0 mg/kg and 5.0 mg/kg ﬂuoxetine animals. Fluoxetine at
dose 5.0 mg/kg increased activity in unstressed animals than
similarly treated 1.0 mg/kg ﬂuoxetine administrated animals
and activity were signiﬁcant after a one week administration.
Fig. 4 shows effects of repeated ﬂuoxetine administration
on activity in novel environment (open ﬁeld) of rats exposed
to CMS as monitored on next day of 1st and 7th stress.
Data on number of square crossing as analyzed by three-
way ANOVA (repeated measures design) showed that effects
of repeated monitoring (F= 42.79; df = 3, 32; p< 0.01),
ﬂuoxetine (F= 25.62; df = 2, 32; p< 0.01) and stress
(F= 92.154; df = 1, 32; p< 0.01) were signiﬁcant.
Interaction among CMS, ﬂuoxetine and repeated monitoring
(F= 21.10; df = 6, 64; p< 0.01) were also signiﬁcant. Post-
hoc analysis by Newman–Keuls test showed that exposure to
CMS decreased activity in water administrated animals after
7th day of stress. Administration of ﬂuoxetine increased activ-
ity in unstressed animals and values were signiﬁcant after 7th
day of administration at dose 5.0 mg/kg. Exposure ofﬂuoxetine administrated animals (1.0 mg/kg as well as
5.0 mg/kg) to CMS decreased activity after 7th day of stress.
4. Discussion
The aim of the present study was to investigate that whether
ﬂuoxetine administration could reverse the behavioral deﬁcits
induced by chronic mild stress (CMS). In this experiment we
used CMS to produce behavioral deﬁcits which are considered
to be a valid and useful experimental model of depression (van
Eldik and Wainwright, 2003; Surget et al., 2008). Results from
the present study show that exposure to CMS reduces food
intake, growth rate and locomotor activity as compared to
unstressed animals indicating a behavioral consequence of
CMS as predicted for an animal model of depression.
Willner et al. (1991) have reported that exposure to stressors
induced signiﬁcant changes in behavioral parameters, such as
decreased locomotive and explorative activity, a decline in
food intake, water intake and sexual activity (Willner et al.,
1991). Joca and his colleagues have reported that CMS-
induced hypolocomotive effects could be due to the decrease
in serotonergic function resulting in the development of
depressive symptoms (Joca et al., 2003). In the present study,
group of stressed rats showed signiﬁcant decreases in locomo-
tor and exploratory activities as compared with the control
group. In stressed but untreated animals, we observed a
decrease in time spent in light box of light dark transition
box as well as in open arm of elevated plus maze ant after
but difference was signiﬁcant after 7th day of stress compared
with unstressed animal.
A number of studies have reported that ﬂuoxetine and
other selective serotonin reuptake inhibitors (SSRIs) produce
anorexia in human and experimental animals (Caccia et al.,
1992; Clifton et al., 1989; Clifton and Lee, 1997; Currie
et al., 1998; Halford et al., 2007; Heisler et al., 1999). SSRI-
induced anorexia in thought to result, at least in part, from
blockage of the reuptake of serotonin (5-HT) into nerve term-
inals and a subsequent elevation of extracellular 5-HT in the
somatodentritic region which desensitize somatodentritic
receptors to increase 5-HT availability in terminal region
(Clifton et al., 1989; Heisler et al., 1999; Gobert et al., 1997;
Hernandez et al., 1991; Lee and Clifton, 1992; Malagie et al.,
1995; Tao et al., 2002; Trillat et al., 1998; Wong et al., 1995).
Serotonergic mechanisms play an important role in the
modulation of locomotor activity at a number of levels in
the neuroaxis including the spinal cord, the basal ganglia, lim-
bic structures, and in the frontal cortex (Brocco et al., 2002;
Geyer, 1996; Wallis, 1994). Results from the present study
showed that ﬂuoxetine induced higher activity was more
signiﬁcant in familiar and novel environment at both doses
that is low (1.0 mg/kg) as well as high (5.0 mg/kg) in unstressed
than CMS animals. SSRIs administered acutely or sub-
chronically are known to have limited beneﬁcial effects or even
adverse effects on anxiety and depression (Griebel, 1995;
Dulawa et al., 2004). However, chronic SSRIs treatments are
effective in depressed or anxious patients (Barr et al., 1997;
Gelﬁn et al., 1998) as well as in highly emotional animal mod-
els (Dulawa et al., 2004; Popa et al., 2008). Unstressed as well
as CMS group animals showed an anxiolytic effect in open
ﬁeld followed ﬂuoxetine administration than saline injected
animals. An increase in activity or time spent in the center of
Anxiolytic proﬁle of ﬂuoxetine in rat model of chronic mild stress 577the open ﬁeld indicates reductions in anxiety and / or increases
in exploration (Dulawa et al., 1999). Fluoxetine is devoid of
afﬁnity for serotonin receptors (Beasly et al., 1992; Wong
et al., 1983), but it acts as an indirect agonist, stimulating
multiple 5-HT receptors. Because serotonergic neurotransmis-
sion is based on multiple 5-HT receptors types and subtypes,
5-HT-1A-1F, 5-HT-2A-2C AND 5-HT-3-7 (Gothert, 1992;
Gothert and Schlicker, 1987; Hoyer et al., 1994; Peroutka,
1991), the study of the speciﬁc blockade of 5-HT receptors
could be useful to explain the mechanisms of action of this
monoamine on learning and memory.
Anxiolytic effects of ﬂuoxetine were monitored in light dark
transition box and an elevated plus maze test. We ﬁnd that
repeated administration of ﬂuoxetine produced anxiolytic
effects but not on single administration in both unstressed as
well as CMS group animals as compared to water admini-
strated control animals. A number of studies have reported
that repeated ﬂuoxetine administration leads to a decrease in
spontaneous ﬁring activity of serotonergic neurons (Blier
et al., 1988; Chaput et al., 1991; Fuller, 1994; Perry and
Fuller, 1992).
In conclusion, the present study demonstrated that CMS
exposure resulted into behavioral deﬁcits and produced
depressive-like symptoms. Fluoxetine, an SSRI, administra-
tion attenuated behavioral deﬁcits induced by CMS.
Anxiolytic effects of repeated ﬂuoxetine administration were
greater in unstressed than CMS animals.
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